MedTrace Logo

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

NCT03771781 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-02-21

No results posted yet for this study

Summary

Bioequivalence Study of Empagliflozin Tablets and Jardiance® Under Fasting and Fed Conditions in Chinese Healthy Volunteers.

Conditions

Interventions

DRUG

Empagliflozin Tablets

Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.

DRUG

Empagliflozin Tab 25 MG

Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-16
Primary Completion
2018-05-25
Completion
2018-05-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03771781 on ClinicalTrials.gov